Boryung Pharma (보령제약) said this week that the company has recently completed an extensive recruitment of 74 new employees to be deployed in the drug sales team for Kanarb (카나브), a novel product for hypertension. 

These 74-member sales team members have been under an intensive product training for Kanarb (카나브).

Boryung (보령제약) filed an application with the health agency in charge of the necessary approval last March to market Kanarb (카나브), in a bid to achieve KRW 100 billion won in domestic sales in the next five years.

Kanarb is one of several drugs in the class of angiotensin II receptor blocker (ARB).

Fimasartan, the active ingredient, has shown an "excellent" efficacy in reducing blood pressure level, while not causing any significant side effects, the company officials said.

If Kanarb is approved by the government, and be available on the market, it would mark as the 15th new medicine developed by a domestic drug manufacturer.

The drug will likely be available on the market during the third quarter of this year, market observers said.

Most medicines developed by Korean companies have been unsuccessful in the market, with many firms failing to recoup investment they had spent on developing new drugs.

<기사원문 - 관련기사에 첨부되어 있습니다>